171 related articles for article (PubMed ID: 10029573)
41. The PML/RARalpha fusion protein inhibits tumor necrosis factor-alpha-induced apoptosis in U937 cells and acute promyelocytic leukemia blasts.
Testa U; Grignani F; Samoggia P; Zanetti C; Riccioni R; Lo Coco F; Diverio D; Felli N; Passerini CG; Grell M; Pelicci PG; Peschle C
J Clin Invest; 1998 May; 101(10):2278-89. PubMed ID: 9593784
[TBL] [Abstract][Full Text] [Related]
42. Tyrosine kinase inhibitor STI571 potentiates the pharmacologic activity of retinoic acid in acute promyelocytic leukemia cells: effects on the degradation of RARalpha and PML-RARalpha.
Gianni' M; Kalaç Y; Ponzanelli I; Rambaldi A; Terao M; Garattini E
Blood; 2001 May; 97(10):3234-43. PubMed ID: 11342454
[TBL] [Abstract][Full Text] [Related]
43. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL.
He LZ; Guidez F; Tribioli C; Peruzzi D; Ruthardt M; Zelent A; Pandolfi PP
Nat Genet; 1998 Feb; 18(2):126-35. PubMed ID: 9462740
[TBL] [Abstract][Full Text] [Related]
44. Acute promyelocytic leukemia with a PLZF-RARalpha fusion protein.
Jansen JH; Löwenberg B
Semin Hematol; 2001 Jan; 38(1):37-41. PubMed ID: 11172538
[TBL] [Abstract][Full Text] [Related]
45. Mutations in the E-domain of RAR portion of the PML/RAR chimeric gene may confer clinical resistance to all-trans retinoic acid in acute promyelocytic leukemia.
Imaizumi M; Suzuki H; Yoshinari M; Sato A; Saito T; Sugawara A; Tsuchiya S; Hatae Y; Fujimoto T; Kakizuka A; Konno T; Iinuma K
Blood; 1998 Jul; 92(2):374-82. PubMed ID: 9657734
[TBL] [Abstract][Full Text] [Related]
46. Activation of
Zhang F; Zhu YL; Deng WL; Zhu J; Zhang J
J Leukoc Biol; 2017 Mar; 101(3):655-664. PubMed ID: 27605212
[TBL] [Abstract][Full Text] [Related]
47. The clinically relevant CHK1 inhibitor MK-8776 induces the degradation of the oncogenic protein PML-RARα and overcomes ATRA resistance in acute promyelocytic leukemia cells.
Franza M; Albanesi J; Mancini B; Pennisi R; Leone S; Acconcia F; Bianchi F; di Masi A
Biochem Pharmacol; 2023 Aug; 214():115675. PubMed ID: 37406967
[TBL] [Abstract][Full Text] [Related]
48. PML/RARα-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia.
Bräuer-Hartmann D; Hartmann JU; Wurm AA; Gerloff D; Katzerke C; Verga Falzacappa MV; Pelicci PG; Müller-Tidow C; Tenen DG; Niederwieser D; Behre G
Cancer Res; 2015 Aug; 75(16):3411-24. PubMed ID: 26041820
[TBL] [Abstract][Full Text] [Related]
49. Effects on differentiation by the promyelocytic leukemia PML/RARalpha protein depend on the fusion of the PML protein dimerization and RARalpha DNA binding domains.
Grignani F; Testa U; Rogaia D; Ferrucci PF; Samoggia P; Pinto A; Aldinucci D; Gelmetti V; Fagioli M; Alcalay M; Seeler J; Grignani F; Nicoletti I; Peschle C; Pelicci PG
EMBO J; 1996 Sep; 15(18):4949-58. PubMed ID: 8890168
[TBL] [Abstract][Full Text] [Related]
50. Interferon augments PML and PML/RAR alpha expression in normal myeloid and acute promyelocytic cells and cooperates with all-trans retinoic acid to induce maturation of a retinoid-resistant promyelocytic cell line.
Nason-Burchenal K; Gandini D; Botto M; Allopenna J; Seale JR; Cross NC; Goldman JM; Dmitrovsky E; Pandolfi PP
Blood; 1996 Nov; 88(10):3926-36. PubMed ID: 8916959
[TBL] [Abstract][Full Text] [Related]
51. Selenite promotes all-trans retinoic acid-induced maturation of acute promyelocytic leukemia cells.
Misra S; Selvam AK; Wallenberg M; Ambati A; Matolcsy A; Magalhaes I; Lauter G; Björnstedt M
Oncotarget; 2016 Nov; 7(46):74686-74700. PubMed ID: 27732960
[TBL] [Abstract][Full Text] [Related]
52. Targeting PML/RARalpha transcript with DNAzymes results in reduction of proliferation and induction of apoptosis in APL cells.
Kabuli M; Yin JA; Tobal K
Hematol J; 2004; 5(5):426-33. PubMed ID: 15448669
[TBL] [Abstract][Full Text] [Related]
53. PRAM-1 is a novel adaptor protein regulated by retinoic acid (RA) and promyelocytic leukemia (PML)-RA receptor alpha in acute promyelocytic leukemia cells.
Moog-Lutz C; Peterson EJ; Lutz PG; Eliason S; Cavé-Riant F; Singer A; Di Gioia Y; Dmowski S; Kamens J; Cayre YE; Koretzky G
J Biol Chem; 2001 Jun; 276(25):22375-81. PubMed ID: 11301322
[TBL] [Abstract][Full Text] [Related]
54. Down-stream regions of the POZ-domain influence the interaction of the t(11;17)-associated PLZF/RARalpha fusion protein with the histone-deacetylase recruiting co-repressor complex.
Puccetti E; Sennewald B; Fosca-Ferrara F; Boehrer S; Bianchini A; Hoelzer D; Ottmann OG; Nervi C; Ruthardt M
Hematol J; 2001; 2(6):385-92. PubMed ID: 11920278
[TBL] [Abstract][Full Text] [Related]
55. [Effects of arsenic trioxide on K562 cells stably expressing two promyelocytic leukemia-specific fusion proteins].
Zhou L; Chen G; Pan L
Zhonghua Yi Xue Za Zhi; 2000 Apr; 80(4):297-300. PubMed ID: 11798775
[TBL] [Abstract][Full Text] [Related]
56. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells.
Zheng X; Seshire A; Rüster B; Bug G; Beissert T; Puccetti E; Hoelzer D; Henschler R; Ruthardt M
Haematologica; 2007 Mar; 92(3):323-31. PubMed ID: 17339181
[TBL] [Abstract][Full Text] [Related]
57. Repression of CDKN2C caused by PML/RARα binding promotes the proliferation and differentiation block in acute promyelocytic leukemia.
Wang X; Tan Y; Li Y; Li J; Jin W; Wang K
Front Med; 2016 Dec; 10(4):420-429. PubMed ID: 27888400
[TBL] [Abstract][Full Text] [Related]
58. Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradation.
Wang QQ; Zhou XY; Zhang YF; Bu N; Zhou J; Cao FL; Naranmandura H
Oncotarget; 2015 Sep; 6(28):25646-59. PubMed ID: 26213848
[TBL] [Abstract][Full Text] [Related]
59. Characterization of the retinoid binding properties of the major fusion products present in acute promyelocytic leukemia cells.
Benedetti L; Levin AA; Scicchitano BM; Grignani F; Allenby G; Diverio D; Lo Coco F; Avvisati G; Ruthardt M; Adamo S; Pelicci PG; Nervi C
Blood; 1997 Aug; 90(3):1175-85. PubMed ID: 9242550
[TBL] [Abstract][Full Text] [Related]
60. PML/RARalpha fusion protein mediates the unique sensitivity to arsenic cytotoxicity in acute promyelocytic leukemia cells: Mechanisms involve the impairment of cAMP signaling and the aberrant regulation of NADPH oxidase.
Li L; Wang J; Ye RD; Shi G; Jin H; Tang X; Yi J
J Cell Physiol; 2008 Nov; 217(2):486-93. PubMed ID: 18636556
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
